6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Pharmacotherapy for Cocaine Addiction
Cocaine addiction presents a significant challenge in treatment, as there are currently no FDA-approved medications specifically for its management. However, various pharmacotherapies are being explored to mitigate cravings and reduce relapse rates. Medications such as antidepressants, dopamine agonists, and anti-anxiety drugs can be used to treat the underlying neurochemical imbalances associated with cocaine addiction. Behavioral therapies, such as cognitive-behavioral therapy (CBT), are often integrated with pharmacological interventions to address the psychological components of addiction. Combining pharmacotherapy with psychosocial treatments has shown promise in improving long-term recovery outcomes for individuals with cocaine addiction.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States